Adaptive Biotechnologies Corporation
NASDAQ Global SelectTotal Valuation
Adaptive Biotechnologies Corporation carries a market capitalization of 3.89B, placing it among publicly traded companies globally. Its enterprise value stands at 3.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.89B |
| Enterprise Value | 3.43B |
Share Statistics
Adaptive Biotechnologies Corporation currently has 159.70M shares outstanding.
| Shares Outstanding | 159.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 14.08 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -265.30 |
| P/OCF Ratio | -227.93 |
Enterprise Valuation
| EV / Sales | 14.48 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Adaptive Biotechnologies Corporation maintains a current ratio of 10.07, meaning it holds 10.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 109.84, indicating elevated leverage, while an interest coverage ratio of -1.05 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.07 |
| Quick Ratio | 9.24 |
| Debt / Equity | 109.84 |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.05 |
Financial Efficiency
| Return on Equity (ROE) | -26.78 |
| Return on Assets (ROA) | -9.69 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -13.42 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 13.11 |
Stock Price Statistics
Adaptive Biotechnologies Corporation's stock has gained approximately 86.48233% over the past 52 weeks. The 50-day moving average sits at 23.38, while the 200-day moving average is 17.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | 86.48233% |
| 50-Day Moving Average | 23.38 |
| 200-Day Moving Average | 17.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Adaptive Biotechnologies Corporation generated 236.53M in revenue and converted that into -24.07M in net income, yielding earnings per share of -0.15. EBITDA reached -9.25M, while operating income came in at -21.69M.
| Revenue | 236.53M |
| Gross Profit | 181.44M |
| Operating Income | -21.69M |
| Pretax Income | -24.05M |
| Net Income | -24.07M |
| EBITDA | -9.25M |
| EBIT | -21.69M |
| Earnings Per Share (EPS) | -0.15 |
Cash Flow
Adaptive Biotechnologies Corporation produced -14.61M in operating cash flow over the past twelve months. After subtracting -1.84M in capital expenditures, free cash flow totaled -16.45M - equivalent to -0.11 per share.
| Operating Cash Flow | -14.61M |
| Capital Expenditures | -1.84M |
| Free Cash Flow | -16.45M |
| FCF Per Share | -0.11 |
Margins
Adaptive Biotechnologies Corporation operates with a gross margin of 76.71, reflecting its pricing power and cost economics. The operating margin of -9.17 and net profit margin of -10.17 provide insight into operational efficiency.
| Gross Margin | 76.71 |
| Operating Margin | -9.17 |
| Pretax Margin | -10.17 |
| Profit Margin | -10.17 |
| EBITDA Margin | -3.91 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.90 |
| FCF Yield | -0.38 |
Scores
Adaptive Biotechnologies Corporation posts an Altman Z-Score of 2.21, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.21 |